Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report) dropped 0% on Tuesday . The stock traded as low as $10.55 and last traded at $10.55. Approximately 600 shares changed hands during trading, a decline of 95% from the average daily volume of 11,567 shares. The stock had previously closed at $10.5501.
Drugs Made in America Acquisition Price Performance
The firm’s 50 day moving average price is $10.52 and its two-hundred day moving average price is $10.52.
Drugs Made in America Acquisition Company Profile
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
Read More
- Five stocks we like better than Drugs Made in America Acquisition
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- This makes me furious
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
